Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Target Price of $110.91

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given an average recommendation of “Moderate Buy” by the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $110.91.

A number of research analysts have recently issued reports on GPCR shares. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Weiss Ratings lowered shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC increased its position in Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after purchasing an additional 313,600 shares during the period. Handelsbanken Fonder AB acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $1,041,000. SEB Asset Management AB acquired a new stake in shares of Structure Therapeutics in the 1st quarter valued at approximately $11,811,000. Squarepoint Ops LLC boosted its stake in shares of Structure Therapeutics by 454.5% in the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after buying an additional 102,929 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Trading Down 2.4%

Shares of GPCR opened at $35.06 on Friday. The company’s 50 day simple moving average is $46.25 and its 200-day simple moving average is $46.43. The firm has a market cap of $2.44 billion, a PE ratio of -35.06 and a beta of -1.45. Structure Therapeutics has a 12-month low of $24.63 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts forecast that Structure Therapeutics will post -1.87 EPS for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.